1. Treatment impact on COVID-19 evolution in hemodialysis patients
- Author
-
Albert Buchard, Hamza Sakhi, Tomek Kofman, Laurence Nicolet, Emmanuel Dupuis, Remy Boula, Djamal Dahmane, Julie Sohier-Attias, Philippe Attias, Karim El Sakhawi, Ali Zineddine Diddaoui, Arezki Adem, Henri Boulanger, Jean François Desassis, Salima Ahriz-Saksi, Luc Fromentin, Dominique Joly, Larbi Lamriben, Afshin Massoumi, Khalil El Karoui, Mokhtar Chawki, Ali Hafi, Sylvain Chawki, Rachida Nebbad, Abderrahmane Ghazali, Frederic Besson, Patrick Michaut, David Attaf, Karim Dardim, Mohamad Khair Rifard, and Philippe Rieu
- Subjects
Adult ,Male ,2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,medicine.medical_treatment ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,MEDLINE ,Article ,Betacoronavirus ,Renal Dialysis ,Internal medicine ,Pandemic ,medicine ,Humans ,Pandemics ,Aged ,Retrospective Studies ,Aged, 80 and over ,hemodialysis ,biology ,SARS-CoV-2 ,business.industry ,COVID-19 ,Retrospective cohort study ,angiotensin ,Middle Aged ,biology.organism_classification ,ACE Inhibitors ,Nephrology ,Kidney Failure, Chronic ,Female ,France ,Hemodialysis ,Coronavirus Infections ,business - Published
- 2020
- Full Text
- View/download PDF